Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

@article{Habermann2009LenalidomideOM,
  title={Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.},
  author={Thomas Matthew Habermann and Izidore S Lossos and Glen R Justice and Julie Marie Vose and Peter H. Wiernik and Kyle McBride and Kenton Wride and Annette Ervin-Haynes and Kenichi Takeshita and Dennis Pietronigro and Jerome B. Zeldis and Joseph M Tuscano},
  journal={British journal of haematology},
  year={2009},
  volume={145 3},
  pages={344-9}
}
Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma with a poor prognosis following first relapse. We present a subgroup analysis of an open-label phase II trial investigating the efficacy and safety of lenalidomide in patients with relapsed or refractory MCL. Oral lenalidomide 25 mg was self-administered once daily on days 1-21 every 28 d for up to 52 weeks, according to tolerability or until disease progression. The primary endpoint was overall response rate (ORR) and secondary… CONTINUE READING
109 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 109 extracted citations

Similar Papers

Loading similar papers…